RenovoRx opened lower at $1.21, compared with its previous close of $1.22. In the last trading session, the stock traded between $1.10 and $1.22. It showed a downward intraday trend.
An investment of $100 made 5 years ago in RenovoRx is now worth
$ 13.76
Resulting in a loss of
$ 86.24 (86.24%)
Note: Past profits do not guarantee future returns.
Rating from 4 Analysts
Today's Change
$-0.05 (-4.10%)
Day High
$1.22
Day Low
$1.10
Day Open
$1.21
Prev Close
$1.22
Volume
4,60,228
1W Return
-10.76%
1M Return
-6.47%
3M Return
2.18%
6M Return
37.65%
1Y Return
9.35%
Market Cap ($ Mn)
56
PE Ratio
-
PB Ratio
8.37
PEG Ratio
-
ROE
-133.68%
ROCE
-120.72%
EPS (TTM)
$-0.08
1 Week
-10.76%
1 Month
-6.47%
3 Months
2.18%
6 Months
37.65%
9 Months
20.62%
RenovoRx Q3 Results: Sales up 300% to $1.066 million, EPS misses
Quarterly sales reached $1.066 million, up 300.75% YoY. Adjusted EPS of $(0.07) missed consensus estimate by 16.67%. Revenue slightly beat analyst expectations by 0.14%. Loss per share remained unchanged from the prior year period.
7 days agoRenovoRx enrolls first patient in PRISM-TAMP pancreatic cancer trial
RenovoRx announces first patient enrollment in PRISM-TAMP trial. Study sponsored by University of Vermont focuses on PDAC regression. Second patient progressing toward treatment one week after start. Trial evaluates neoadjuvant TAMP therapy using RenovoCath device.
1mo agoRenovoRx trial data shows 51% local drug extraction, lower systemic exposure
RenovoRx TIGeR-PaC Phase III sub-study shows 51% local drug extraction via TAMP platform. Intra-arterial delivery resulted in significantly lower systemic exposure despite 50% higher infusion rate. Statistically significant correlation found between drug metabolite levels and CA 19-9 tumor marker reduction. Trial enrollment closed; top-line data expected in second half of 2027.
2mo agoRenovoRx regains Nasdaq compliance after meeting bid price rule
RenovoRx regained Nasdaq compliance after stock bid price stayed at or above $1.00 for 10 consecutive days. Record Q2 2026 revenue reached $909,000, up from $1.1 million in total 2025 sales. Company completed enrollment in Phase III TIGeR-PaC trial in August 2026. Topline data for IAG expected in second half of 2027 following trial completion in H1 2027.
2mo agoRenovoRx secures USPTO patent allowance for cancer therapy delivery method
RenovoRx Inc has received a USPTO Notice of Allowance for a key patent application related to its cancer treatment delivery methods. This development enhances the intellectual property coverage for its TAMP platform and RenovoCath device, supporting its targeted oncology therapy business.
2mo agoRenovoRx Q2 revenue surges 115% YoY to $909,000; raises FY26 guidance
RenovoRx reported record Q2 2026 revenue of $909,000, up 115% YoY, driven by increased active customers and procedural utilization. The company raised full-year guidance to $3.75M-$4.25M and narrowed its adjusted EPS loss to $(0.05). Gross margin expanded to 84.3%, while SG&A costs rose to support commercial scaling.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in RenovoRx is now worth
$ 13.76
Resulting in a loss of
$ 86.24 (86.24%)
Note: Past profits do not guarantee future returns.
